Top 10 Low Price Stocks To Own Right Now

Top 10 Low Price Stocks To Own Right Now: Halozyme Therapeutics Inc.(HALO)

Halozyme Therapeutics, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of recombinant human enzymes that transiently modify tissue under the skin to facilitate injection of other therapies or correct diseased tissue structures for clinical benefits. The company primarily offers recombinant human hyaluronidase, an enzyme that degrades hyaluronan, which is a matrix component in the skin, and facilitates the dispersion and absorption of drugs and fluids. Its portfolio of products and product candidates are developed based principally on intellectual property covering the family of human enzymes known as hyaluronidases. The company also provides Ultrafast Insulin program, a Phase II clinical trial product for the treatment of diabetes mellitus; and Enhanze technology, a proprietary drug delivery platform for subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as sma ll molecules and fluids. It offers PEGPH20, a new molecular entity that is in Phase I trial for the systemic treatment of tumors; and HTI-501, a recombinant human proteinase, which is in Phase 1/2 clinical trial used for the treatment of edematous fibrosclerotic panniculopathy (cellulite). The company has collaborative partnerships with F. Hoffmann-La Roche, Ltd and Hoffmann-La Roche, Inc.; ViroPharma Incorporated; and Intrexon Corporation to apply Enhanze technology to the partners? biological therapeutic compounds. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.

Advisors' Opinion:

• [By Sheila Dang]

  Halozyme Therapeutics Inc. (HALO) CEO Helen Torley and CFO David Ramsey together bought 75,000 shares of the company on Sept. 17, at a cost of $668,500.

• [By Anna Prior] !

  J.P. Morgan (JPM) initiated coverage of Halozyme Therapeutics Inc.(HALO) with an overweight rating and a $13 price target, saying in a note to clients that the company’s proprietary pipeline appears to be garnering increased attention. Halozyme shares climbed 5.2% to $9.77 premarket.

• [By Charley Blaine]

  Biotechnology stocks, meanwhile, are getting slaughtered. Gilead Sciences (NASDAQ: GILD) is down 22 percent. Halozyme Therapeutics (NASDAQ: HALO), which has been working on a drug to treat pancreatic cancer, is off 59 percent since peaking on Jan. 24.

• [By Monica Gerson]

  Halozyme Therapeutics (NASDAQ: HALO) shares dropped 2.04% to $8.12 after the company reported a clinical hold of PEGPH20 pancreatic cancer trial amid voluntary halt.

source from Top Stocks For 2015:http://www.topstocksblog.com/top-10-low-price-stocks-to-own-right-now-2.html